Denmark · Delayed Price · Currency is DKK Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of DKK 1.19 trillion. The enterprise value is 1.32 trillion.
| Market Cap | 1.19T |
| Enterprise Value | 1.32T |
Important Dates
The next confirmed earnings date is Wednesday, August 5, 2026.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | Mar 27, 2026 |
Share Statistics
Novo Nordisk has 4.43 billion shares outstanding. The number of shares has decreased by -0.20% in one year.
| Current Share Class | 3.36B |
| Shares Outstanding | 4.43B |
| Shares Change (YoY) | -0.20% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 28.56% |
| Float | 3.18B |
Valuation Ratios
The trailing PE ratio is 9.83 and the forward PE ratio is 13.09. Novo Nordisk's PEG ratio is 3.43.
| PE Ratio | 9.83 |
| Forward PE | 13.09 |
| PS Ratio | 3.64 |
| PB Ratio | 5.88 |
| P/TBV Ratio | 16.33 |
| P/FCF Ratio | 19.77 |
| P/OCF Ratio | 10.09 |
| PEG Ratio | 3.43 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.52, with an EV/FCF ratio of 21.83.
| EV / Earnings | 10.82 |
| EV / Sales | 4.03 |
| EV / EBITDA | 7.52 |
| EV / EBIT | 8.17 |
| EV / FCF | 21.83 |
Financial Position
The company has a current ratio of 0.79, with a Debt / Equity ratio of 0.72.
| Current Ratio | 0.79 |
| Quick Ratio | 0.54 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 0.83 |
| Debt / FCF | 2.42 |
| Interest Coverage | 38.38 |
Financial Efficiency
Return on equity (ROE) is 71.40% and return on invested capital (ROIC) is 40.42%.
| Return on Equity (ROE) | 71.40% |
| Return on Assets (ROA) | 19.25% |
| Return on Invested Capital (ROIC) | 40.42% |
| Return on Capital Employed (ROCE) | 48.33% |
| Weighted Average Cost of Capital (WACC) | 5.74% |
| Revenue Per Employee | 4.83M |
| Profits Per Employee | 1.80M |
| Employee Count | 67,900 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 1.17 |
Taxes
In the past 12 months, Novo Nordisk has paid 33.72 billion in taxes.
| Income Tax | 33.72B |
| Effective Tax Rate | 21.66% |
Stock Price Statistics
The stock price has decreased by -44.94% in the last 52 weeks. The beta is 0.35, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -44.94% |
| 50-Day Moving Average | 266.30 |
| 200-Day Moving Average | 312.42 |
| Relative Strength Index (RSI) | 43.90 |
| Average Volume (20 Days) | 5,739,710 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novo Nordisk had revenue of DKK 327.80 billion and earned 121.96 billion in profits. Earnings per share was 27.41.
| Revenue | 327.80B |
| Gross Profit | 272.72B |
| Operating Income | 161.45B |
| Pretax Income | 155.68B |
| Net Income | 121.96B |
| EBITDA | 173.88B |
| EBIT | 161.45B |
| Earnings Per Share (EPS) | 27.41 |
Balance Sheet
The company has 21.63 billion in cash and 146.38 billion in debt, with a net cash position of -124.76 billion or -28.14 per share.
| Cash & Cash Equivalents | 21.63B |
| Total Debt | 146.38B |
| Net Cash | -124.76B |
| Net Cash Per Share | -28.14 |
| Equity (Book Value) | 203.07B |
| Book Value Per Share | 45.71 |
| Working Capital | -47.84B |
Cash Flow
In the last 12 months, operating cash flow was 118.46 billion and capital expenditures -58.03 billion, giving a free cash flow of 60.43 billion.
| Operating Cash Flow | 118.46B |
| Capital Expenditures | -58.03B |
| Depreciation & Amortization | 12.43B |
| Net Borrowing | 24.16B |
| Free Cash Flow | 60.43B |
| FCF Per Share | 13.63 |
Margins
Gross margin is 83.20%, with operating and profit margins of 49.25% and 37.20%.
| Gross Margin | 83.20% |
| Operating Margin | 49.25% |
| Pretax Margin | 47.49% |
| Profit Margin | 37.20% |
| EBITDA Margin | 53.04% |
| EBIT Margin | 49.25% |
| FCF Margin | 18.43% |
Dividends & Yields
This stock pays an annual dividend of 11.70, which amounts to a dividend yield of 4.30%.
| Dividend Per Share | 11.70 |
| Dividend Yield | 4.30% |
| Dividend Growth (YoY) | 2.63% |
| Years of Dividend Growth | 8 |
| Payout Ratio | 42.47% |
| Buyback Yield | 0.20% |
| Shareholder Yield | 4.50% |
| Earnings Yield | 10.21% |
| FCF Yield | 5.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Novo Nordisk is 311.78, which is 15.80% higher than the current price. The consensus rating is "Hold".
| Price Target | 311.78 |
| Price Target Difference | 15.80% |
| Analyst Consensus | Hold |
| Analyst Count | 26 |
| Revenue Growth Forecast (3Y) | 1.09% |
| EPS Growth Forecast (3Y) | 0.69% |
Stock Splits
The last stock split was on September 13, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Sep 13, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Novo Nordisk has an Altman Z-Score of 4.66 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.66 |
| Piotroski F-Score | 4 |